Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Effat Rasul

Internal Medicine Lake Charles, LA Medical Doctor

NPI 1699086561 CMS profile 1290666

524 Dr Michael Debakey Dr, Lake Charles, LA 70601

Open in the dashboard

General payments

$2,822

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Effat Rasul of Lake Charles, LA is reported in the CMS Open Payments database as having received $2,822 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $801 45
2024 General $706 39
2023 General $722 41
2022 General $374 14
2021 General $53 3
2019 General $165 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Effat Rasul
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Effat Rasul were reported at $801. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Effat Rasul Internal Medicine median Middle half National median
2019 $165 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $53 $135 $37–$521 $132
2022 $374 $141 $42–$496 $149
2023 $722 $149 $45–$519 $160
2024 $706 $154 $47–$537 $164
2025 $801 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $372 21 payments
  2. Novo Nordisk Inc $357 15 payments
  3. Lilly USA, LLC $315 17 payments
  4. Abbott Laboratories $165 8 payments
  5. Sumitomo Pharma America, Inc. $136 6 payments
  6. Esperion Therapeutics, Inc. $129 9 payments
  7. Boston Scientific Corporation $120 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $114 7 payments
  9. Amgen Inc. $108 7 payments
  10. Noven Therapeutics, LLC $93 4 payments
  11. Other $913 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,822 146 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $284 15 payments
  2. Ozempic $275 11 payments
  3. BREZTRI $217 12 payments
  4. FARXIGA $155 9 payments
  5. FreeStyle Libre 3 $142 7 payments
  6. GEMTESA $136 6 payments
  7. NEXLETOL $129 9 payments
  8. WATCHMAN $120 1 payment
  9. ZEPBOUND $103 6 payments
  10. Xelstrym $93 4 payments
  11. Other $1,665 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

5,972

Median for Internal Medicine: 777

Drug cost

$726,103

Median for Internal Medicine: $73,373

Branded share of claims

20.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 179 $218,878
Ozempic Semaglutide Brand 99 $130,196
Farxiga Dapagliflozin Propanediol Brand 58 $62,810
Januvia Sitagliptin Phosphate Brand 47 $60,366
Jardiance Empagliflozin Brand 47 $52,277
Eliquis Apixaban Brand 44 $35,789
Nexlizet Bempedoic Acid/Ezetimibe Brand 30 $22,250
Trulicity Dulaglutide Brand 16 $15,003
Tradjenta Linagliptin Brand 12 $13,972
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $13,355

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$146,227

Of which drugs: $5,244

Medicare patients

311

Average age 73

Services billed

3,681

225 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 41%
Chronic kidney disease 41%
Diabetes 31%
Depression 25%
Cancer 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 54 54 $4,418
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 29 130 $687
Injection, ceftriaxone sodium, per 250 mg J0696 Office 39 174 $57

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $68
$68 58 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $61
$61 47 —
NEXLETOL
  • Esperion Therapeutics, Inc. $57
$57 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $25
  • Lundbeck LLC $22
$47 — —
MOUNJARO
  • Lilly USA, LLC $47
$47 179 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record